We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to use a before-and-after study to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
How to use a quasi-experimental study to evaluate your digital health product.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Find out about the long-term effects some people can have after having COVID-19.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
The review of the safety of isotretinoin has concluded.
Advises on how planning can manage potential noise impacts in new development.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
How to use a crossover randomised controlled trial to evaluate your digital health product.
Using an ecological momentary assessment to evaluate your digital health product.
Guidance relating to blood clotting, myocarditis and Guillain-Barré Syndrome (GBS) after COVID-19 vaccination.
Information for British nationals affected by rape or sexual assault abroad, including how to access medical treatment and legal advice in the UK.
How to use an N-of-1 study to evaluate your digital health product.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
How to use a cost benefit analysis to evaluate your digital health product.
Climate change is happening and is due to human activities; along with warming, many other changes are occurring such as melting polar ice, rising sea levels and more frequent floods, droughts and heatwaves.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).